Company: Eidos Therapeutics, Inc.
Symbol: EIDX
Description: They are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
Trade Date: 6/20
Shares: 6.25 million
Price Range: $15.00-$17.00
Underwriter(s): J.P. Morgan, BofA Merrill Lynch
Co-Manager(s): Barclays
Terms Added: 6-8-18
Business: They are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. They seek to treat this well-defined family of diseases at their collective source by stabilizing TTR, a therapeutic approach that is supported by genetic evidence as well as previous clinical trials. Their product candidate, AG10, is an orally-administered small molecule designed to potently stabilize TTR, with the potential to halt the progression of ATTR and be a promising treatment for this family of diseases. The development of AG10 is led by their proven management team who are responsible for developing over 30 molecules through Investigational New Drug, or IND, applications, and more than ten approved drugs. Together with patients and physicians, they aim to bring a well-tolerated, effective and disease-modifying treatment for ATTR to market as quickly as possible.
Insider Buying: Certain of their existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $50 million in shares of their common stock in this offering at the initial public offering price per share.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish